Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta
This article was originally published in The Pink Sheet Daily
Amylin claims Lilly has breached its agreement to commercialize exenatide as the Big Pharma gears up to launch the Boehringer-developed diabetes drug Tradjenta.
You may also be interested in...
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.